These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15758629)

  • 21. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
    Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
    Treiber G; Röcken C; Wex T; Malfertheiner P
    Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.
    Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Panagiotakos D; Fotopoulou A; Chrysohoou C; Bazinis A; Daskalopoulou D; Paraskevas E
    World J Gastroenterol; 2007 Jun; 13(23):3164-70. PubMed ID: 17589893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire.
    Pistevou-Gombaki K; Eleftheriadis N; Plataniotis GA; Sofroniadis I; Kouloulias VE
    Palliat Med; 2003 Apr; 17(3):257-62. PubMed ID: 12725479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
    Allgaier HP; Becker G; Blum HE
    Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.
    Lersch C; Schmelz R; Erdmann J; Hollweck R; Schulte-Frohlinde E; Eckel F; Nader M; Schusdziarra V
    Hepatogastroenterology; 2004; 51(58):1099-103. PubMed ID: 15239254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide inhibits the growth and development of three types of experimental liver metastasis.
    Frizelle FA
    Br J Surg; 1995 Nov; 82(11):1577. PubMed ID: 8535822
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.
    Treiber G; Wex T; Röcken C; Fostitsch P; Malfertheiner P
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):699-708. PubMed ID: 16835748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
    Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
    J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
    [No Abstract]   [Full Text] [Related]  

  • 31. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
    Jia WD; Zhang CH; Xu GL; Ge YS; Wang W
    Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide treatment of hepatocellular carcinoma.
    Kouroumalis E; Samonakis D; Skordilis P
    Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide in hepatocellular carcinoma.
    Shouval D
    Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
    [No Abstract]   [Full Text] [Related]  

  • 37. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
    Guo TK; Hao XY; Ma B; Yang KH; Li YP; Li HL; Gu YH; Cai H; Liu YL; Li Y; Zhan WP
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1685-92. PubMed ID: 19536563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer.
    Treiber G; Wex T; Malfertheiner P
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):271-81. PubMed ID: 18642029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
    Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
    Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.